Browsing by Author "Hardy-Werbin, Max"

Sort by: Order: Results:

  • Comparison of different methods for defining hyperprogressive disease in NSCLC
    Rocha, Pedro P.; Ramal, Didac; Ripoll, Enric; Moliner, Laura; Corbera-Lloret, Alex; Hardy-Werbin, Max; Orrillo, Mayra; Taus García, Álvaro; Zuccarino, Flavio; Gibert Fernandez, Joan 1988-; Perera Bel, Júlia; Casadevall Aguilar, David; Arriola Aperribay, Edurne (Elsevier, 2020)
    Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, ...
  • Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients
    Montero, Maria Milagro; Hardy-Werbin, Max; Gonzalez-Gallardo, Soledad; Torres, Erica; Rueda, Rebeca; Arenas-Miras, María Del Mar; Arietta-Aldea, Itziar; Castañeda, Silvia; Gómez Junyent, Joan; Gómez-Zorrilla, Silvia; Guerri-Fernandez, Robert; Sánchez-Martínez, Francesca; López Montesinos, Inmaculada; Pelegrín, Iván; Sendra, Elena; Sorlí, Luisa; Villar García, Judit; Bellosillo Paricio, Beatriz; Horcajada Gallego, Juan Pablo (Nature Research, 2023)
    Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay ...
  • MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
    Hardy-Werbin, Max; del Rey-Vergara, Raúl; Galindo-Campos, Miguel A.; Moliner Jiménez, Laura; Arriola Aperribay, Edurne (MDPI, 2019)
    Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies ...
  • Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients
    Hardy-Werbin, Max; Quiroga, Vanesa; Cirauqui, Beatriz; Romeo, Margarita; Felip, Eudald; Teruel, Iris; García, Juan José; Erasun, Carlos; España, Sofia; Cucurull, Marc; Montprad, Elisabeth; Pardo, Juan Carlos; Carballo, Dania; Velarde, José María; Margeli, Mireia (Nature Research, 2019)
    T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic ...
  • Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
    Hardy-Werbin, Max; Rocha, Pedro P.; Arpí Llucià, Oriol; Taus García, Álvaro; Nonell Mazelón, Lara; Duran Jordà, Xavier, 1974-; Villanueva, Xavier; Joseph-Pietras, Deborah; Nolan, Luke; Danson, Sarah; Griffiths, Richard; López-Botet, Miguel; Rovira Guerín, Ana; Albanell Mestres, Joan; Ottensmeier, Christian; Arriola Aperribay, Edurne (Taylor & Francis, 2019)
    Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory ...